[1]彭娟,谭胜蓝,周宏灏,等.华法林药物基因组学和个体化用药[J].中国药理学通报,2013,(02):169-172.
　PENG Juan,TAN Sheng lan,ZHOU Hong Hao,et al.Pharmacogenomics of warfarin and its personalized treatment[J].Chinese Pharmacological Bulletin,2013,(02):169-172.
点击复制

华法林药物基因组学和个体化用药()
分享到：

《中国药理学通报》[ISSN:/CN:]

卷:
期数:
2013年02期
页码:
169-172
栏目:
讲座与综述
出版日期:
2013-02-25

文章信息/Info

Title:
Pharmacogenomics of warfarin and its personalized treatment
作者:
彭娟; 谭胜蓝; 周宏灏; 李智
中南大学临床药理研究所，湖南 长沙410078
Author(s):
PENG Juan; TAN Shenglan;  ZHOU HongHao; LI Zhi
Institute of Clinical Pharmacology，Central South University，Changsha410078，China
关键词:
华法林; 个体化治疗; 基因多态性; 剂量模型 ; VKORC1; CYP2C9
Keywords:
warfarin;  personalized treatment;  genetic polymorphism;  dose algorithm; VKORC1; CYP2C9
分类号:
R05；R394.2；R973.2
文献标志码:
A
摘要:
华法林是临床使用最广泛的口服抗凝药，其治疗窗窄，剂量个体差异大，容易发生出血或栓塞的风险。CYP2C9和VKORC1基因多态性明显影响华法林剂量。其他参与维生素摄入和循环，华法林转运的基因变异，以及microRNA也可能影响华法林剂量。该文结合国内外各种华法林稳定剂量预测模型研究，总结影响华法林剂量相关基因的最新研究进展，旨在为华法林个体化治疗提供参考和指导依据。
Abstract:
Warfarin is the most widely used oral anticoagulant with narrow therapeutic window, wide interindividual variability and high risks of bleeding or thromboembolism. Polymorphisms in CYP2C9 and VKORC1 are the major determinants of warfarin dosage requirement. Other genetic factors involving in vitamin K intake and recycle, and warfarin transportation may influence warfarin stable maintenance dosage as well. microRNA might also play a role. Based on numerous warfarin stable dosage prediction algorithms studies, this review updates the studies of warfarin pharmacogenomics and its personalized treatment, with the aim of providing evidence for clinical practice.

参考文献/References:

［1］Takeuchi F, Mcginnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose［J］. PLoS Genet, 2009, 5(3): e1000433.
[2]Cha P C, Mushiroda T, Takahashi A, et al. Genomewide association study identifies genetic determinants of warfarin responsiveness for Japanese［J］. Hum Mol Genet, 2010, 19(23): 4735-44.
[3]SullivanKlose T H, Ghanayem B I, Bell D A, et al. The role of the CYP2C9Leu359 allelic variant in the tolbutamide polymorphism［J］. Pharmacogenetics, 1996, 6(4): 341-9.
[4]Wadelius M, Chen L Y, Lindh J D, et al. The largest prospective warfarin-treated cohort supports genetic forecasting［J］. Blood, 2009, 113(4): 784-92.
[5]Zhu Y, Shennan M, Reynolds K K, et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes［J］. Clin Chem, 2007, 53(7): 1199-205.
[6]Wei M, Ye F, Xie D, et al. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: Derivation in Han Chinese patients with non valvular atrial fibrillation［J］. Thromb Haemost， 2012, 107(6): 1083-91.
[7]Cen H J, Zeng W T, Leng X Y, et al. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement［J］. Br J Clin Pharmacol, 2010, 70(2): 234-40.
[8]Xiong Y, Wang M, Fang K, et al. A systematic genetic polymorphism analysis of the CYP2C9 gene in four different geographical Han populations in mainland China［J］. Genomics, 2011, 97(5): 277-81.
[9]Limdi N A, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups［J］. Blood, 2010, 115(18): 3827-34.
[10]Lee M T, Chen C H, Chou C H, et al. Genetic determinants of warfarin dosing in the HanChinese population［J］. Pharmacogenomics 2009, 10(12): 1905-13.
[11]Wadelius M, Chen L Y, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism［J］. Hum Genet, 2007, 121(1): 23-34.
[12]Yuan H Y, Chen J J, Lee M T, et al. A novel functional VKORC1 promoter polymorphism is associated with interindividual and interethnic differences in warfarin sensitivity［J］. Hum Mol Genet, 2005, 14(13): 1745-51.
[13]Rieder M J, Reiner A P, Gage B F, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose［J］. N Engl J Med, 2005, 352(22): 2285-93.
[14]D′Andrea G, D′Ambrosio R L, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the doseanticoagulant effect of warfarin［J］. Blood, 2005, 105(2): 645-9.
[15]Zhong S L, Yu X Y, Liu Y, et al. Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients［J］. Pharmacogenet Genomics, 2012, 22(3): 176-82.
[16]Yang L, Ge W, Yu F, et al. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirementa systematic review and meta analysis［J］. Thromb Res, 2010, 125(4): e159-e66.
[17]Mcdonald M G, Rieder M J, Nakano M, et al. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant［J］. Mol Pharmacol, 2009, 75(6): 1337-46.
[18]Singh O, Sandanaraj E, Subramanian K, et al. Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients［J］. Drug Metab Pharmacokinet, 2011, 26(2): 130-6.
[19]Scott S A, Khasawneh R, Peter I, et al. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups［J］. Pharmacogenomics. 2010, 11(6): 781-91.
[20]Borgiani P, Ciccacci C, Forte V, et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population［J］. Pharmacogenomics, 2009, 10(2): 261-6.
[21]范岚，彭向东，郭志华，等. CYP450氧化还原酶的遗传多态对药物代谢的影响［J］. 中国药理学通报，2009，25(9): 1131-3.
[21]Fan L，Peng X D，Guo Z H，et al. Genetic polymorphisms of cytochrome P450 oxidoreductase and its effect on drug metabolism［J］.Chin Pharmacol Bull，2009，25(9): 1131-3.
[22]Zhang X, Li L, Ding X, et al. Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose［J］. Drug Metab Dispos. 2011, 39(8): 1433-9.
[23]Kohnke H, Sorlin K, Granath G, et al. Warfarin dose related to apolipoprotein E (APOE) genotype［J］. Eur J Clin Pharmacol, 2005, 61(5-6): 381-8.
[24]Kimura R, Miyashita K, Kokubo Y, et al. Genotypes of vitamin K epoxide reductase, gammaglutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients［J］. Thromb Res, 2007, 120(2): 181-6.
[25]Huang S W, Xiang D K, Wu H L, et al.［Impact of five genetic polymorphisms on interindividual variation in warfarin maintenance dose］［J］. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2011, 28(6): 661-5.
[26]Gu Q, Kong Y, Schneede J, et al. VKORC11639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China［J］. Eur J Clin Pharmacol, 2010, 66(12): 1217-27.
[27]胡永芳，周宏灏. CYP3A4，CYP3A5和MDR1基因多态性对环孢素处置的影响［J］. 中国药理学通报， 2005，21(3): 257-61.
[27]Hu Y F，Zhou H H. Contribution of genetic polymorphismsof the CYP3A4, CYP3A5 and MDR1 genes to cyclosporine disposition［J］. Chin Pharmacol Bull，2005，21(3): 257-61. ［28］Wadelius M, Sorlin K, Wallerman O, et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors［J］. Pharmacogenomics J, 2004, 4(1): 40-8.
[29]Rajewsky N. microRNA target predictions in animals［J］. Nat Genet, 2006, 38 Suppl: S8-S13.
[30]Miao L, Yang J, Huang C, et al. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients［J］. Eur J Clin Pharmacol, 2007, 63(12): 1135-41.
[31]Huang S W, Chen H S, Wang X Q, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients［J］. Pharmacogenet Genomics, 2009, 19(3): 226-34.
[32]You J H, Wong R S, Waye M M, et al. Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients［J］. J Thromb Thrombolysis, 2011, 31(1): 113-8.
[33]Gage B F, Eby C, Johnson J A, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin［J］. Clin Pharmacol Ther, 2008, 84(3): 326-31.
[34]Klein T E, Altman R B, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data［J］. N Engl J Med, 2009, 360(8): 753-64.
[35]Cho H J, On Y K, Bang O Y, et al. Development and comparison of a warfarindosing algorithm for Korean patients with atrial fibrillation［J］. Clin Ther, 2011, 33(10): 1371-80.
[36]Ohno M, Yamamoto A, Ono A, et al. Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients［J］. Eur J Clin Pharmacol, 2009, 65(11): 1097-103.

相似文献/References:

[1]张敏,王果,周宏灏.华法林个体差异的遗传药理学因素[J].中国药理学通报,2008,(07):0.
　ZHANG Min,WANG Guo,ZHOU Hong hao.The genetic factors of warfarin individual variation[J].Chinese Pharmacological Bulletin,2008,(02):0.
[2]陈豪,谭志荣,周宏灏.含黄素单氧化酶3（FMO3）结构、功能及其基因多态性的研究进展[J].中国药理学通报,2008,(10):0.
　CHEN Hao,TAN Zhi rong,ZHOU Hong hao.Advance in flavincontaining monooxygenase 3 (FMO3):structure/function and genetic polymorphisms[J].Chinese Pharmacological Bulletin,2008,(02):0.
[3]胡蓉,许哲,赵立子,等.POR基因多态性与华法林维持剂量关系的研究[J].中国药理学通报,2014,(05):706.
　HU Rong,XU Zhe,ZHAO Li zi,et al.Associations of POR polymorphisms and warfarin stable maintenance dose in Han Chinese patients[J].Chinese Pharmacological Bulletin,2014,(02):706.
[4]邢永华,孟爱民.单细胞网络谱分析方法及应用[J].中国药理学通报,2014,(10):1342.
　XING Yong-hua,MENG Ai-min.Application of single cell network profiling[J].Chinese Pharmacological Bulletin,2014,(02):1342.

备注/Memo

备注/Memo:
收稿日期:2012-08-01,修回日期:2012-09-10 基金项目：国家高技术研究发展计划（863计划）（No 2012AA02A518）和湖南省高校创新平台开放基金（No 11K073） 作者简介：彭娟（1989-），女，硕士，研究方向：遗传药理学和临床药理学,Tel: 073184805380 Email: 849328768@qq.com; 李智（1970-），男，博士，副教授，硕士生导师，研究方向：遗传药理学和临床药理学,通讯作者,Tel: 073184805380,Email:lizhi489@163.com
更新日期/Last Update: 2013-02-25